HFmrEF

1. Comprehensive Executive Overview

Heart Failure with mildly reduced Ejection Fraction (HFmrEF) represents a distinct clinical phenotype within the spectrum of heart failure (HF) syndromes. Historically classified as a "gray zone" or transition phase between Heart Failure with reduced Ejection Fraction (HFrEF) and Heart Failure with preserved Ejection Fraction (HFpEF), HFmrEF has now been formally recognized by major cardiovascular societies—including the American College of Cardiology (ACC), the American Heart Association (AHA), and the European Society of Cardiology (ESC)—as a unique clinical entity.

Under the clinical coding system, HFmrEF is frequently classified under the ICD-10 code I50.2 (Systolic heart failure) or I50.4 (Combined systolic and diastolic heart failure), depending on the patient's dominant hemodynamics and clinical presentation.

Defining HFmrEF

By clinical consensus, HFmrEF is defined by:
1. The presence of classic symptoms and/or signs of heart failure.
2. A Left Ventricular Ejection Fraction (LVEF) of 41% to 49%.
3. Biochemical evidence of myocardial wall stress (elevated natriuretic peptides) and/or objective evidence of structural heart disease or diastolic dysfunction.

HFrEF HFmrEF HFpEF
(LVEF ≤ 40%) (LVEF 41-49%) (LVEF ≥ 50%)
|----------------------|----------------------|

Epidemiological data indicates that HFmrEF accounts for approximately 10% to 25% of the global heart failure population. Patients with HFmrEF represent a heterogeneous cohort: some are transitioning "upward" from HFrEF due to myocardial recovery (sometimes referred to as HF with improved EF, or HFimpEF), while others are transitioning "downward" from HFpEF due to progressive systolic decline. Understanding the unique pathophysiological drivers of this condition is critical for optimizing patient outcomes.

2. Detailed Pathophysiology, Etiology, and Risk Factors

Pathophysiology

The pathophysiology of HFmrEF is highly complex, sharing characteristics of both HFrEF (systolic dysfunction and adverse ventricular remodeling) and HFpEF (diastolic stiffness, microvascular inflammation, and systemic comorbidities).

• Systolic and Diastolic Overlap: At an LVEF of 41–49%, patients exhibit mild impairment of longitudinal myocardial strain and contractility. Concurrently, they demonstrate elevated left ventricular end-diastolic pressure (LVEDP) due to impaired active relaxation and increased passive stiffness of the myocardium.
• Neurohormonal Activation: Similar to HFrEF, there is moderate activation of the Renin-Angiotensin-Aldosterone System (RAAS) and the Sympathetic Nervous System (SNS), though typically less pronounced than in severe HFrEF.
• Systemic Inflammation & Microvascular Dysfunction: Driven by comorbidities such as obesity, diabetes, and chronic kidney disease, a systemic inflammatory state leads to coronary microvascular endothelial dysfunction. This reduces nitric oxide (NO) bioavailability in adjacent cardiomyocytes, impairing cyclic guanosine monophosphate (cGMP) pathway signaling and worsening diastolic stiffness.

Etiology

The underlying causes of HFmrEF are diverse and dictate the patient’s clinical trajectory:
* Ischemic Heart Disease (IHD): Coronary artery disease and prior myocardial infarction (MI) are highly prevalent in HFmrEF, particularly in patients whose phenotype closely mirrors HFrEF.
* Hypertensive Heart Disease: Chronic, uncontrolled hypertension leads to left ventricular hypertrophy (LVH) and subsequent transition to systolic impairment.
* Valvular Heart Disease: Chronic aortic stenosis, aortic regurgitation, or mitral regurgitation can alter loading conditions, leading to myocardial remodeling.
* Cardiomyopathies: Familial, toxic (e.g., chemotherapy, alcohol), or infiltrative (e.g., early-stage amyloidosis) cardiomyopathies can present within this intermediate ejection fraction range.

Risk Factors

The clinical profile of HFmrEF is shaped by a combination of cardiovascular and metabolic risk factors:
* Advanced Age: Incidence increases progressively in patients over 65.
* Biological Sex: Males are more likely to present with ischemic-driven HFmrEF, whereas females are more likely to present with non-ischemic, hypertensive-driven HFmrEF.
* Metabolic Syndrome & Type 2 Diabetes: Promotes systemic inflammation and accelerates myocardial fibrosis.
* Chronic Kidney Disease (CKD): Contributes to chronic fluid overload and accelerated arterial stiffness.

3. Signs, Symptoms, and Clinical Presentation

The clinical presentation of HFmrEF is virtually indistinguishable from other forms of heart failure. Symptoms arise primarily from pulmonary venous congestion and low cardiac output.

Symptomatology

• Dyspnea on Exertion (DOE): The most common presenting symptom, caused by elevated left atrial pressure transmitting backward into the pulmonary vasculature during physical activity.
• Orthopnea & Paroxysmal Nocturnal Dyspnea (PND): Sensation of breathlessness when lying flat, or sudden awakening gasping for air, indicating redistribution of fluid into the lungs.
• Fatigue and Exercise Intolerance: Caused by an inability of the heart to adequately increase cardiac output to meet metabolic demands.
• Peripheral Edema: Bilateral swelling of the lower extremities (ankles and shins) due to fluid retention.

Clinical Signs on Physical Examination

• Jugular Venous Distension (JVD): Elevated jugular venous pressure (JVP) reflecting elevated right atrial and central venous pressures.
• Pulmonary Crackles (Rales): Heard on auscultation, indicating alveolar fluid transudation.
• S3 and S4 Gallops: An S3 gallop suggests volume overload, while an S4 gallop reflects atrial contraction into a stiff, non-compliant left ventricle.
• Hepatojugular Reflux: Sustained distension of neck veins when pressure is applied to the abdomen, indicating venous congestion.

NYHA Functional Classification

The New York Heart Association (NYHA) classification is utilized to grade the severity of functional impairment in patients with HFmrEF:

• Class I: No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or dyspnea.
• Class II: Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation, or dyspnea.
• Class III: Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes fatigue, palpitation, or dyspnea.
• Class IV: Unable to carry on any physical activity without discomfort, or symptoms of heart failure at rest.

4. Standard Diagnostic Evaluation & Workup

A comprehensive diagnostic workup is essential to confirm the diagnosis of HFmrEF, exclude mimics, and identify correctable underlying etiologies.

[Suspected HF: Dyspnea, Fatigue, Edema]
│
▼
[ECG & Natriuretic Peptides]
│
▼
[Transthoracic Echocardiogram (TTE)]
│
┌──────────┴──────────┐
▼ ▼
[LVEF 41-49%] [Other LVEF Ranges]
│ (HFrEF / HFpEF)
▼
[Confirm Elevated BNP/NT-proBNP & Diastolic Dysfunction]
│
▼
[Diagnose HFmrEF]

1. Imaging Modalities

• Transthoracic Echocardiogram (TTE): The gold standard first-line imaging modality. It provides precise quantification of LVEF (using the biplane Simpson's method), assesses chamber volumes, evaluates diastolic function (via $E/e'$ ratio and deceleration time), and identifies valvular pathology.
• Cardiac Magnetic Resonance (CMR): Indicated when echocardiographic images are suboptimal or when an infiltrative disease, myocarditis, or myocardial viability needs assessment. CMR offers the most precise measurement of LVEF and identifies focal or diffuse myocardial fibrosis via Late Gadolinium Enhancement (LGE).
• Chest X-ray: Evaluates for cardiomegaly, pulmonary congestion, pleural effusions, or alternative pulmonary pathology.

2. Laboratory Assays & Biomarkers

• Natriuretic Peptides (BNP and NT-proBNP): Gold standard biomarkers for diagnosing and monitoring heart failure.
  • B-type Natriuretic Peptide (BNP): Typically elevated ($\ge 35\text{ pg/mL}$ in ambulatory patients; $\ge 100\text{ pg/mL}$ in acute presentations).
  • N-terminal pro-B-type Natriuretic Peptide (NT-proBNP): Elevated ($\ge 125\text{ pg/mL}$ in ambulatory patients; $\ge 300\text{ pg/mL}$ in acute settings).
• Basic Metabolic Panel (BMP): Assess serum creatinine, estimated glomerular filtration rate (eGFR), and electrolytes (sodium, potassium) to guide medical therapy.
• Complete Blood Count (CBC): Screen for anemia, which can exacerbate heart failure symptoms.
• Thyroid-Stimulating Hormone (TSH): Rule out thyroid dysfunction as a cause of high-output or low-output failure.
• Iron Studies (Ferritin and Transferrin Saturation): Screen for iron deficiency, which is highly prevalent and independently associated with poor outcomes in HF.

3. Advanced and Invasive Diagnostics

• Coronary Angiography: Recommended for patients with HFmrEF who have angina or a high suspicion of coronary artery disease to evaluate for revascularization options.
• Invasive Hemodynamic Exercise Testing: Right heart catheterization during exercise may be used in borderline cases to confirm elevated left ventricular filling pressures (Pulmonary Capillary Wedge Pressure [PCWP] $\ge 15\text{ mmHg}$ at rest or $\ge 25\text{ mmHg}$ during exercise).
• Endomyocardial Biopsy (EMB): Rarely indicated; reserved for suspected acute giant cell myocarditis, necrotizing eosinophilic myocarditis, or rapidly progressive infiltrative diseases.

5. Therapeutic Interventions

The management of HFmrEF has evolved rapidly. Current clinical guidelines advocate for a multi-faceted approach involving guideline-directed medical therapy (GDMT), device interventions, and structured lifestyle modifications.

Pharmacotherapy (Guideline-Directed Medical Therapy)

Historically, treatment for HFmrEF was extrapolated from HFrEF trials. However, recent landmark clinical trials have provided dedicated data for this intermediate range.

                 ┌────────────────────────────────────────┐
                 │          HFmrEF Pharmacotherapy        │
                 └───────────────────┬────────────────────┘
                                     │
   ┌─────────────────────────┬───────┴─────────┬────────────────────────┐
   ▼                         ▼                 ▼                        ▼

[SGLT2 Inhibitors] [ARNI / ACEi / ARB] [Beta-Blockers] [MRAs]
(Class I - Dapagliflozin/ (Class IIb - Reduces (Class IIb - Controls (Class IIb - Reduces
Empagliflozin) hospitalizations) heart rate) hospitalizations)

1. Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors

• Medications: Empagliflozin, Dapagliflozin.
• Clinical Nuance: Class I Recommendation. Based on the DELIVER and EMPEROR-Preserved clinical trials, SGLT2 inhibitors significantly reduce the composite endpoint of cardiovascular death and heart failure hospitalization in patients with an LVEF > 40%, making them a foundational pillar of therapy for HFmrEF.

2. Angiotensin Receptor-Neprilysin Inhibitors (ARNI) / ACE Inhibitors / ARBs

• Medications: Sacubitril/Valsartan (ARNI), Enalapril, Ramipril (ACEi), Candesartan, Valsartan (ARB).
• Clinical Nuance: Class IIb Recommendation. Subgroup analyses from the PARAGON-HF trial demonstrated that Sacubitril/Valsartan provides a significant reduction in heart failure hospitalizations in patients at the lower end of the preserved/mildly reduced EF spectrum (LVEF 41–57%). ACEi and ARBs may be considered to reduce the risk of HF hospitalization.

3. Beta-Blockers

• Medications: Carvedilol, Metoprolol Succinate, Bisoprolol.
• Clinical Nuance: Class IIb Recommendation. Meta-analyses of landmark beta-blocker trials indicate that these agents reduce cardiovascular mortality and all-cause mortality in patients with HFmrEF who are in sinus rhythm.

4. Mineralocorticoid Receptor Antagonists (MRAs)

• Medications: Spironolactone, Eplerenone.
• Clinical Nuance: Class IIb Recommendation. Data from the TOPCAT trial suggest that MRAs reduce heart failure hospitalizations in patients with ejection fractions in the mildly reduced range.

5. Diuretics

• Medications: Loop diuretics (Furosemide, Bumetanide, Torsemide).
• Clinical Nuance: Essential for patients presenting with clinical signs of fluid retention to achieve and maintain euvolemia.

Device and Surgical Interventions

• Revascularization (PCI or CABG): Strongly indicated in patients with an ischemic etiology of HFmrEF who exhibit viable myocardium and target coronary lesions.
• Valvular Intervention: Transcatheter Aortic Valve Replacement (TAVR) or surgical valve repair/replacement for patients with severe hemodynamically significant valvular disease.
• Implantable Cardioverter-Defibrillators (ICD) & Cardiac Resynchronization Therapy (CRT): Generally not routinely indicated for primary prevention of sudden cardiac death if the LVEF remains consistently $> 35\%$. However, they may be indicated if the patient has a secondary prevention indication or if the LVEF deteriorates into the HFrEF range.

Lifestyle and Self-Care Management

• Sodium and Fluid Restriction: Typically, sodium restriction to $< 2,000\text{ mg/day}$ and fluid restriction to $1.5 - 2.0\text{ L/day}$ are recommended for symptomatic or fluid-overloaded patients.
• Daily Weight Monitoring: Patients should track daily weights. A weight gain of $> 3\text{ lbs}$ in 24 hours or $> 5\text{ lbs}$ in one week should prompt immediate clinical contact.
• Structured Exercise & Cardiac Rehabilitation: Participation in supervised cardiac rehab improves functional capacity, endothelial function, and overall quality of life.
• Comorbidity Management: Aggressive control of blood pressure (target $< 130/80\text{ mmHg}$), glycemic control in diabetes, and treatment of obstructive sleep apnea (OSA).

6. Comprehensive FAQ Section

Q1: What is the difference between HFmrEF, HFrEF, and HFpEF?

Answer: The primary clinical distinction lies in the Left Ventricular Ejection Fraction (LVEF), which measures the percentage of blood pumped out of the left ventricle with each contraction.
* HFrEF (Reduced EF) is defined by an $\text{LVEF} \le 40\%$, characterized by a dilated left ventricle with impaired pumping capacity.
* HFmrEF (Mildly Reduced EF) is defined by an $\text{LVEF}$ of $41\% \text{ to } 49\%$, representing a transitional or mixed phenotype.
* HFpEF (Preserved EF) is defined by an $\text{LVEF} \ge 50\%$, where the heart pumps normally but is stiff and cannot fill adequately during diastole.

Q2: Can HFmrEF be reversed or cured?

Answer: While HFmrEF may not always be "cured" in a permanent structural sense, it is highly treatable, and the ejection fraction can improve. Many patients with HFmrEF experience myocardial recovery (transitioning to "Heart Failure with improved Ejection Fraction" or HFimpEF) when treated with guideline-directed medical therapy (GDMT), especially if the underlying cause—such as tachycardia, alcohol-induced cardiomyopathy, or acute ischemia—is corrected.

Q3: What is a normal ejection fraction, and how is it measured?

Answer: A normal Left Ventricular Ejection Fraction (LVEF) typically ranges from 50% to 70%. An LVEF of 41% to 49% is considered mildly reduced. Ejection fraction is most commonly measured non-invasively using a Transthoracic Echocardiogram (TTE). In cases where clearer visualization is required, a Cardiac Magnetic Resonance (CMR) scan or a nuclear medicine scan (MUGA scan) may be performed.

Q4: Why are SGLT2 inhibitors considered the first-line treatment for HFmrEF?

Answer: SGLT2 inhibitors (such as Empagliflozin and Dapagliflozin) are the only class of medications to receive a strong Class I recommendation specifically for patients with an LVEF of >40%. Large clinical trials (DELIVER and EMPEROR-Preserved) conclusively demonstrated that these medications reduce the combined risk of cardiovascular death and hospitalization for heart failure, regardless of the patient's diabetic status.

Q5: What are the first warning signs that a patient's HFmrEF is worsening?

Answer: Warning signs of decompensation include:
* Unexplained, rapid weight gain (e.g., 3 pounds in a single day or 5 pounds in a week), which indicates fluid retention.
* Increased shortness of breath during normal daily activities or while resting.
* Needing to prop oneself up with extra pillows to sleep comfortably at night (orthopnea).
* Worsening swelling in the feet, ankles, calves, or abdomen.
* Persistent coughing or wheezing with pink, frothy sputum.

Q6: How does high blood pressure contribute to HFmrEF?

Answer: Chronic high blood pressure (hypertension) forces the left ventricle to pump against abnormally high resistance. Over time, this workload causes the heart muscle to thicken (hypertrophy) and stiffen, leading to diastolic dysfunction. Eventually, the muscle fibers stretch and weaken, causing the ejection fraction to drop from the preserved range ($\ge 50\%$) into the mildly reduced range ($41\% - 49\%$).

Q7: Is HFmrEF considered a life-threatening condition?

Answer: Yes, like all forms of heart failure, HFmrEF is a serious, chronic, and potentially life-threatening condition. However, the prognosis has improved dramatically with modern medical therapies. Patients who strictly adhere to their prescribed medical regimens, undergo regular clinical follow-ups, and implement lifestyle modifications have a significantly lower risk of hospitalization and sudden cardiac death.

Q8: What dietary changes are mandatory for patients diagnosed with HFmrEF?

Answer: Patients should adopt a heart-healthy diet, such as the DASH (Dietary Approaches to Stop Hypertension) or Mediterranean diet. Key requirements include:
* Sodium Restriction: Limiting sodium intake to less than 2,000 mg per day to prevent fluid retention.
* Fluid Management: Limiting daily fluid intake to 1.5 to 2 liters if recommended by a cardiologist.
* Alcohol Limitation: Restricting or completely eliminating alcohol, as it can act as a direct myocardial toxin.

Q9: Can patients with HFmrEF safely engage in exercise?

Answer: Yes. Structured, moderate-intensity aerobic exercise (such as walking, cycling, or swimming) is highly beneficial and strongly recommended for patients with stable HFmrEF. Exercise improves cardiovascular efficiency, reduces symptoms, and enhances quality of life. Patients should consult their cardiologist before starting any exercise program or seek a referral to a supervised Cardiac Rehabilitation program.

Q10: What is the long-term prognosis and life expectancy for someone with HFmrEF?

Answer: The long-term prognosis for HFmrEF is generally more favorable than for HFrEF, but it depends heavily on the underlying cause, age, and comorbidities (such as kidney disease or diabetes). Patients whose ejection fraction improves over time (HFimpEF) have the most favorable prognosis. Adherence to guideline-directed medical therapy (GDMT) is the single most critical factor in improving long-term survival and reducing hospital readmissions.

Related Clinical Integration

In the contemporary management of Heart Failure with mildly reduced Ejection Fraction (HFmrEF), clinical protocols emphasize a multi-modal therapeutic approach to improve patient outcomes and reduce hospitalization rates. The integration of ACE Inhibitors / مثبطات الإنزيم المحول للأنجيوتنسين Standard remains a cornerstone of neurohormonal blockade, providing essential hemodynamic support and long-term cardiac remodeling benefits. Furthermore, the clinical paradigm has shifted to include SGLT2 Inhibitors / مثبطات SGLT2 Standard as a foundational therapy, as these agents have demonstrated significant efficacy in reducing cardiovascular mortality and worsening heart failure events across the spectrum of ejection fractions. By aligning these pharmacological interventions within our hospital system, clinicians can ensure evidence-based, standardized care that addresses both the symptomatic and prognostic needs of patients diagnosed with HFmrEF.